Spyre Therapeutics (SYRE) EBIT (2015 - 2026)
Spyre Therapeutics posted quarterly EBIT of -$45.6 million for Q1 2026, up 14.8% year-on-year from -$39.8 million in Q1 2025, and up 20.17% on a QoQ basis from -$57.2 million in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of EBIT data on file, last reported at -$45.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 14.8% year-over-year to -$45.6 million; the trailing twelve-month figure through Mar 2026 stood at -$201.6 million (up 5.94% YoY), and the FY2025 full-year result was -$209.6 million, changed 0.48% from the prior year.
- EBIT for Q1 2026 stood at -$45.6 million, up from -$57.2 million in the prior quarter.
- Across five years, EBIT topped out at -$18.3 million in Q3 2023 and bottomed at -$159.2 million in Q2 2023.
- The 5-year median for EBIT is -$45.6 million (2026), against an average of -$46.5 million.
- The widest annual swing landed in 2023, when EBIT slumped 610.19%; it then surged 72.28% in 2024.
- A 5-year view of EBIT shows it stood at -$19.2 million in 2022, then tumbled by 139.61% to -$45.9 million in 2023, then sank by 33.41% to -$61.3 million in 2024, then gained by 6.66% to -$57.2 million in 2025, then advanced by 20.17% to -$45.6 million in 2026.
- The last three EBIT figures came in at -$45.6 million (Q1 2026), -$57.2 million (Q4 2025), and -$56.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | -45.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.64 Mn |
| Dec 31, 2025 | -57.17 Mn |
| Sep 30, 2025 | -56.89 Mn |
| Jun 30, 2025 | -41.94 Mn |
| Mar 31, 2025 | -53.57 Mn |
| Dec 31, 2024 | -61.25 Mn |
| Sep 30, 2024 | -55.39 Mn |
| Jun 30, 2024 | -44.15 Mn |
| Mar 31, 2024 | -47.77 Mn |
| Dec 31, 2023 | -45.91 Mn |
| Sep 30, 2023 | -18.34 Mn |
| Jun 30, 2023 | -159.25 Mn |
| Mar 31, 2023 | -18.81 Mn |
| Dec 31, 2022 | -19.16 Mn |
| Sep 30, 2022 | -18.76 Mn |
| Jun 30, 2022 | -22.42 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.44 Mn |
| Sep 30, 2021 | -20.29 Mn |
| Jun 30, 2021 | -6.71 Mn |
| Mar 31, 2021 | -18.21 Mn |
| Dec 31, 2020 | -22.78 Mn |
| Sep 30, 2020 | -18.12 Mn |
| Jun 30, 2020 | -21.56 Mn |
| Mar 31, 2020 | -19.02 Mn |
| Dec 31, 2019 | -21.91 Mn |
| Sep 30, 2019 | -22.15 Mn |
| Jun 30, 2019 | -18.62 Mn |
| Mar 31, 2019 | -17.66 Mn |
| Dec 31, 2018 | -15.31 Mn |
| Sep 30, 2018 | -12.24 Mn |
| Jun 30, 2018 | -9.67 Mn |
| Mar 31, 2018 | -8.25 Mn |
| Dec 31, 2017 | -6.63 Mn |
| Sep 30, 2017 | -8.00 Mn |
| Jun 30, 2017 | -6.72 Mn |
| Mar 31, 2017 | -6.33 Mn |
| Dec 31, 2016 | -5.54 Mn |
| Sep 30, 2016 | -6.30 Mn |
| Jun 30, 2016 | -5.50 Mn |
| Mar 31, 2016 | -4.57 Mn |
| Dec 31, 2015 | -4.00 Mn |
| Sep 30, 2015 | -3.42 Mn |
| Jun 30, 2015 | -1.43 Mn |
| Mar 31, 2015 | -2.47 Mn |